<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Belzutifan: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Belzutifan: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Belzutifan: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="132468" href="/d/html/132468.html" rel="external">see "Belzutifan: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="block black-box-warn drugH1Div" id="F56078682"><span class="drugH1">ALERT: US Boxed Warning</span>
<div class="collapsible">
<span class="collapsible-title">Embryo-fetal toxicity:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Exposure to belzutifan during pregnancy can cause embryo-fetal harm. Verify pregnancy status prior to the initiation of belzutifan. Advise patients of these risks and the need for effective nonhormonal contraception. Belzutifan can render some hormonal contraceptives ineffective.</p></div>
</div>
</div>
<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F56151967"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Welireg</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F57397566"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Welireg</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F56092116"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Antineoplastic Agent, HIF-2alpha Inhibitor</li></ul></div>
<div class="block doa drugH1Div" id="F56142227"><span class="drugH1">Dosing: Adult</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="045bd6ae-3edd-419a-aa75-2a643fc49694">Renal cell carcinoma, advanced</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:0em;">
<b>Renal cell carcinoma, advanced: Oral: </b>120 mg once daily; continue until disease progression or unacceptable toxicity.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="5683067f-95c4-455c-a89d-554c66791a4c">von Hippel-Lindau disease</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>von Hippel-Lindau disease: </b>
<i>Patients with renal cell carcinoma, CNS hemangioblastoma, and pancreatic neuroendocrine tumors requiring treatment</i>
<i>:</i>
<b> Oral: </b>120 mg once daily; continue until disease progression or unacceptable toxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34818478']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34818478'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<i>Missed dose: </i>If a dose is missed, administer as soon as possible on the same day and resume the regular dosing schedule the following day; do not administer additional tablets to make up for the missed dose. If vomiting occurs after administration, do not administer another dose; resume dosing the following day.</p>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<b>Concomitant therapy</b>: Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F56142229"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note:</b> Kidney function estimated using the MDRD equation.</p>
<p style="text-indent:-2em;margin-left:2em;">eGFR ≥30 mL/minute/1.73 m<sup>2</sup>: No dosage adjustment is necessary.</p>
<p style="text-indent:-2em;margin-left:2em;">eGFR 15 to 29 mL/minute/1.73 m<sup>2</sup>: There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p></div>
<div class="block doha drugH1Div" id="F56142230"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">Mild impairment (total bilirubin ≤ ULN and AST &gt; ULN <b>or</b> total bilirubin &gt;1 to 1.5 times ULN and any AST): No dosage adjustment is necessary.</p>
<p style="text-indent:-2em;margin-left:2em;">Moderate or severe impairment (total bilirubin &gt;1.5 times ULN and any AST): There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p></div>
<div class="block dot drugH1Div" id="F56142231"><span class="drugH1">Dosing: Adjustment for Toxicity: Adult</span>
<table border="1" frame="border" rules="all">
<caption>
<b>Belzutifan Dose Reduction Levels for Adverse Reactions</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dose level</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Belzutifan dose</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">Recommended initial starting dose</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">120 mg once daily</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">First dose reduction</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">80 mg once daily</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">Second dose reduction</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">40 mg once daily</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">Third dose reduction</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Permanently discontinue belzutifan</p></td></tr></tbody></table>
<table border="1" frame="border" rules="all">
<caption>
<b>Belzutifan Dose Modifications for Adverse Reactions</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Adverse reaction</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Severity</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dose modification</b></p></th></tr></thead>
<tfoot>
<tr>
<td align="center" colspan="3">
<p style="text-indent:0em;text-align:left;">
<sup>a </sup>May require supplemental oxygen or hospitalization.</p></td></tr></tfoot>
<tbody>
<tr>
<td align="center" rowspan="2">
<p style="text-indent:0em;text-align:left;">Anemia</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Hemoglobin &lt;8 g/dL or transfusion indicated</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Withhold belzutifan until hemoglobin is ≥8 g/dL. Resume at the same or at a reduced dose; or permanently discontinue belzutifan, depending on the severity.</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">Life-threatening or urgent intervention indicated</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Withhold belzutifan until hemoglobin is ≥8 g/dL. Resume at a reduced dose or permanently discontinue belzutifan.</p></td></tr>
<tr>
<td align="center" rowspan="3">
<p style="text-indent:0em;text-align:left;">Hypoxia<sup>a</sup></p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Decreased oxygen saturation with exercise (eg, pulse oximeter &lt;88% or PaO<sub>2</sub> ≤55 mm Hg)</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Consider withholding belzutifan until hypoxia is resolved (eg, pulse oximeter with exercise &gt;88%). Resume at the same or reduced dose, depending on the severity.</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">Decreased oxygen saturation at rest (eg, pulse oximeter &lt;88% or PaO<sub>2</sub> ≤55 mm Hg) or urgent intervention required</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Withhold belzutifan until hypoxia is resolved. Resume at a reduced dose or discontinue belzutifan, depending on the severity.</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">Life-threatening or recurrent symptomatic hypoxia</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Permanently discontinue belzutifan.</p></td></tr>
<tr>
<td align="center" rowspan="2">
<p style="text-indent:0em;text-align:left;">Other adverse reactions</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Grade 3</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Withhold belzutifan until improved to ≤ grade 2. Consider resuming at a reduced dose (reduce by 40 mg). Permanently discontinue belzutifan if grade 3 adverse reaction recurs.</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">Grade 4</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Permanently discontinue belzutifan.</p></td></tr></tbody></table></div>
<div class="block doe drugH1Div" id="F56142228"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block arsc drugH1Div" id="F56576902"><span class="drugH1">Adverse Reactions (Significant): Considerations</span>
<div class="collapsible">
<span class="collapsible-title">Anemia</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Anemia</b> has been reported in clinical trials; grade 3 anemia and severe anemia requiring blood transfusions have occurred.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Dose-related; inhibition of hypoxia-inducible factor 2 alpha (HIF-2α) decreases gene transcription, leading to reduced erythropoietin production and iron metabolism (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28242135']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28242135'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Varied; median 29 to 31 days (range: 1 day to 16.6 months).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i>
<i></i></p>
<p style="text-indent:-2em;margin-left:6em;">• Dual UGT2B17 and CYP2C19 poor metabolizers</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Hypoxia</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Severe <b>hypoxia</b> has been reported, including grade 3 events; may require supplemental oxygen, discontinuation, and/or hospitalization.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Dose-related; inhibition of hypoxia-inducible factor 2 alpha (HIF-2α) prevents oxygen sensing regulating genes from promoting the body’s response to hypoxia.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Varied; median 30.5 days (range: 1 day to 21.1 months).</p></div>
</div>
</div>
<div class="block adr drugH1Div" id="F56092096"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Adverse reactions reported in adults.</p>
<p style="text-indent:0em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Edema (20%)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Decreased serum calcium (21%), decreased serum glucose (22%), decreased serum sodium (31%), increased serum potassium (29%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Constipation (15%), decreased appetite (13%), diarrhea (11%; grades 3/4: 1%), nausea (17%; grades 3/4: &lt;1%), vomiting (11%; grades 3/4: &lt;1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Lymphocytopenia (34%; grades 3/4: 8%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Increased serum alanine aminotransferase (32%), increased serum aspartate aminotransferase (27%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Dizziness (11%), fatigue (43%), headache (12%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Musculoskeletal pain (34%)</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Increased serum creatinine (34%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Dyspnea (16%), hypoxia (15%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Hypertension (6%)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Skin rash (8%)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Weight gain (5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal pain (10%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Anemia (serious: 5%), hemorrhage (9%)</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Visual disturbance (including blurred vision [4%], decreased visual acuity [1%], retinal detachment [&lt;1%], and visual impairment [&lt;1%])</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Pleural effusion (serious: 2%), pneumonia (serious: 4%)</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%: Nervous system: Cerebral hemorrhage, intracranial hemorrhage</p></div>
<div class="block coi drugH1Div" id="F56078685"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">There are no contraindications listed in the manufacturer's US labeling.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling:</i> Hypersensitivity to belzutifan or any component of the formulation.</p></div>
<div class="block war drugH1Div" id="F58968780"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Older adults: Patients ≥65 years of age treated for advanced renal cell carcinoma experienced higher rates of dose interruptions and dose reductions during belzutifan therapy compared to patients &lt;65 years of age.</p></div>
<div class="block foc drugH1Div" id="F56151968"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Welireg: 40 mg [contains fd&amp;c blue #2 (indigo carm) aluminum lake]</p></div>
<div class="block geq drugH1Div" id="F56151966"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block fee drugH1Div" id="F56223255"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Welireg Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">40 mg (per each): $395.48</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F57397567"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Welireg: 40 mg [contains fd&amp;c blue #2 (indigo carm) aluminum lake]</p></div>
<div class="block accres drugH1Div" id="F58968776"><span class="drugH1">Prescribing and Access Restrictions</span>
<p style="text-indent:0em;display:inline">Belzutifan is available through specialty pharmacies/distributors and various specialty institutions/accounts. Examples from the manufacturer may be found at: https://www.merckaccessprogram-welireg.com/hcp/
                  </p></div>
<div class="block adm drugH1Div" id="F56142232"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Oral:</b> Administer at the same time each day, with or without food. Swallow whole; do not chew, crush, or split tablets.</p></div>
<div class="block hazard drugH1Div" id="F56142216"><span class="drugH1">Hazardous Drugs Handling Considerations</span>
<p style="text-indent:0em;">This medication is not on the NIOSH (2016) list; however, it may meet the criteria for a hazardous drug. Belzutifan may cause teratogenicity or reproductive toxicity.</p>
<p style="text-indent:0em;margin-top:2em;">Use appropriate precautions for receiving, handling, storage, preparation, dispensing, transporting, administration, and disposal. Follow NIOSH and USP 800 recommendations and institution-specific policies/procedures for appropriate containment strategy (NIOSH 2016; USP-NF 2020).</p>
<p style="text-indent:0em;margin-top:2em;">
<b>Note:</b> Facilities may perform risk assessment of some hazardous drugs to determine if appropriate for alternative handling and containment strategies (USP-NF 2020). Refer to institution-specific handling policies/procedures.</p></div>
<div class="block meg drugH1Div" id="F56092015"><span class="drugH1">Medication Guide and/or Vaccine Information Statement (VIS)</span>
<p style="text-indent:0em;display:inline">An FDA-approved patient medication guide, which is available with the product and as follows, must be dispensed with this medication:</p>
<p style="text-indent:-2em;margin-left:4em;">Welireg: <a href="/external-redirect?target_url=https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2023%2F215383s006lbl.pdf%23page%3D17&amp;token=3Keqai8ImmXcSvYWi%2Fwqu4%2FKl78T3%2FxdKoOJ7anRxfotUxXubxRcM1QXWd7wk43QVgc6tsrdrPg7%2BP1Afc6EDfaQf417hi8rqBF5A8bXs8ILmyjSARFuV3Ku0yOpca0A&amp;TOPIC_ID=132401" target="_blank">https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/215383s006lbl.pdf#page=17</a></p></div>
<div class="block use drugH1Div" id="F56078684"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Renal cell carcinoma, advanced: </b>Treatment of advanced renal cell carcinoma in adults following a programmed death receptor-1 (PD-1) or programmed death-ligand 1 (PD-L1) and a vascular endothelial growth factor tyrosine kinase inhibitor (VEGF-TKI).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>von Hippel-Lindau disease:</b> Treatment of adult patients with von Hippel-Lindau disease who require therapy for associated renal cell carcinoma, CNS hemangioblastomas, or pancreatic neuroendocrine tumors, not requiring immediate surgery.</p></div>
<div class="block mst drugH1Div" id="F56142206"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Belzutifan may be confused with belimumab, belinostat, belumosudil, busulfan.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">High alert medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F56155917"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of CYP2C19 (minor), CYP3A4 (minor), OATP1B1/1B3 (SLCO1B1/1B3), P-glycoprotein/ABCB1 (minor), UGT2B17; <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential; <b>Induces</b> CYP3A4 (weak)</p></div>
<div class="block dri drugH1Div" id="F56155914"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Antidiabetic Agents: Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Atogepant: CYP3A4 Inducers (Weak) may decrease the serum concentration of Atogepant.  Management: For treatment of episodic migraine, the recommended dose of atogepant is 30 mg once daily or 60 mg once daily when combined with CYP3A4 inducers. When used for treatment of chronic migraine, use of atogepant with CYP3A4 inducers should be avoided.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">CarBAMazepine: CYP3A4 Inducers (Weak) may decrease the serum concentration of CarBAMazepine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CloZAPine: CYP3A4 Inducers (Weak) may decrease the serum concentration of CloZAPine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP2C19 Inhibitors (Moderate): May increase the serum concentration of Belzutifan.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP2C19 Inhibitors (Strong): May increase the serum concentration of Belzutifan.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Hormonal Contraceptives: CYP3A4 Inducers (Weak) may decrease the serum concentration of Hormonal Contraceptives.  Management: Advise patients to use an alternative method of contraception or a back-up method during coadministration, and to continue back-up contraception for 28 days after discontinuing a weak CYP3A4 inducer to ensure contraceptive reliability.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">NiMODipine: CYP3A4 Inducers (Weak) may decrease the serum concentration of NiMODipine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Selpercatinib: CYP3A4 Inducers (Weak) may decrease the serum concentration of Selpercatinib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sirolimus (Conventional): CYP3A4 Inducers (Weak) may decrease the serum concentration of Sirolimus (Conventional). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sirolimus (Protein Bound): CYP3A4 Inducers (Weak) may decrease the serum concentration of Sirolimus (Protein Bound). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tacrolimus (Systemic): CYP3A4 Inducers (Weak) may decrease the serum concentration of Tacrolimus (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ubrogepant: CYP3A4 Inducers (Weak) may decrease the serum concentration of Ubrogepant.  Management: Use an initial ubrogepant dose of 100 mg and second dose (if needed) of 100 mg when used with a weak CYP3A4 inducer.<i> Risk D: Consider therapy modification</i></p></div>
<div class="block rep_considerations drugH1Div" id="F56142209"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;">Verify pregnancy status prior to treatment initiation in patients who could become pregnant.</p>
<p style="text-indent:0em;margin-top:2em;">Patients who could become pregnant should use effective nonhormonal contraception during therapy and for 1 week after the last belzutifan dose. Patients with partners who could become pregnant should also use effective contraception during therapy and 1 week after the last dose of belzutifan. Belzutifan may render some hormonal contraceptives ineffective; consult drug interactions database for detailed information.</p></div>
<div class="block pri drugH1Div" id="F56142210"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;display:inline">Based on animal reproduction studies, in utero exposure to belzutifan may cause fetal harm. Embryo-fetal lethality, reduced fetal body weight, and fetal skeletal malformations were observed when pregnant rats were administered belzutifan at doses resulting in maternal exposures ≥0.2 times the recommended human dose of 120 mg (based on AUC).</p></div>
<div class="block brc drugH1Div" id="F56142211"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">It is not known if belzutifan is present in breast milk.</p>
<p style="text-indent:-2em;margin-left:2em;">Due to the potential for serious adverse reactions in the breastfed infant, breastfeeding is not recommended by the manufacturer during therapy and for 1 week after the last belzutifan dose.</p></div>
<div class="block mop drugH1Div" id="F56142234"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:-2em;margin-left:2em;">Monitor hemoglobin (prior to therapy initiation and periodically throughout treatment); closely monitor patients who are dual UGT2B17 and CYP2C19 poor metabolizers due to the potential increased incidence or severity of anemia. Monitor oxygen saturation (prior to therapy initiation and periodically throughout treatment). Evaluate pregnancy status in patients who could become pregnant. Monitor for signs/symptoms of anemia and hypoxia. Monitor adherence.</p>
<p style="text-indent:-2em;margin-left:2em;">The American Society of Clinical Oncology hepatitis B virus (HBV) screening and management provisional clinical opinion (ASCO [Hwang 2020]) recommends HBV screening with hepatitis B surface antigen, hepatitis B core antibody, total Ig or IgG, and antibody to hepatitis B surface antigen prior to beginning (or at the beginning of) systemic anticancer therapy; do not delay treatment for screening/results. Detection of chronic or past HBV infection requires a risk assessment to determine antiviral prophylaxis requirements, monitoring, and follow-up.</p></div>
<div class="block pha drugH1Div" id="F56142218"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Belzutifan is a small molecule inhibitor of hypoxia-inducible factor 2 alpha (HIF-2α), a transcription factor that regulates genes that promote adaptation to hypoxia. Inactivation of von Hippel-Lindau (VHL) gene results in abnormal stabilization and accumulation of HIF-2α, which drives tumor growth (Srinivasan 2021). Belzutifan binds to HIF-2α and prevents HIF-2α from interacting with hypoxia-inducible factor 1 beta, resulting in reduced transcription and expression of HIF-2α target genes (including genes associated with cellular proliferation, angiogenesis, and tumor growth).</p></div>
<div class="block phk drugH1Div" id="F56142219"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Distribution: V<sub>d</sub>: 119 L.</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: 45%.</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Primarily hepatic via UGT2B17 and CYP2C19 and to a lesser extent by CYP3A4.</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: 14 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak: 1 to 2 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Feces (51.7%; primarily as inactive metabolites); Urine (49.6%; primarily as inactive metabolites).</p>
<p style="text-indent:-2em;margin-left:4em;">Clearance: 6 L/hour.</p></div>
<div class="block phksp drugH1Div" id="F56147747"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Pharmacogenomics: Patients who are UGT2B17, CYP2C19, or dual UGTB17 and CYP2C19 poor metabolizers are estimated to have 2.5-, 1.3-, or 3.2-fold higher belzutifan steady state AUC<sub>0-24h</sub>, respectively, compared to patients who are UGT2B17 normal (extensive) metabolizers and CYP2C19 nonpoor (ultrarapid, rapid, normal, and intermediate) metabolizers.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F58847523"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Welireg</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-USP.1">
<a name="USP.1"></a>&lt;800&gt; Hazardous Drugs—Handling in Healthcare Settings. <i>United States Pharmacopeia and National Formulary </i>(USP 43-NF 38). Rockville, MD: United States Pharmacopeia Convention; 2020:74-92.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28242135">
<a name="28242135"></a>Gupta N, Wish JB. Hypoxia-inducible factor prolyl hydroxylase inhibitors: a potential new treatment for anemia in patients with CKD. <i>Am J Kidney Dis</i>. 2017;69(6):815-826. doi:10.1053/j.ajkd.2016.12.011<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/belzutifan-drug-information/abstract-text/28242135/pubmed" id="28242135" target="_blank">28242135</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32716741">
<a name="32716741"></a>Hwang JP, Feld JJ, Hammond SP, et al. Hepatitis B virus screening and management for patients with cancer prior to therapy: ASCO provisional clinical opinion update. <i>J Clin Oncol</i>. 2020;38(31):3698-3715. doi:10.1200/JCO.20.01757<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/belzutifan-drug-information/abstract-text/32716741/pubmed" id="32716741" target="_blank">32716741</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34818478">
<a name="34818478"></a>Jonasch E, Donskov F, Iliopoulos O, et al; MK-6482-004 Investigators. Belzutifan for renal cell carcinoma in von Hippel-Lindau disease. <i>N Engl J Med</i>. 2021;385(22):2036-2046. doi:10.1056/NEJMoa2103425<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/belzutifan-drug-information/abstract-text/34818478/pubmed" id="34818478" target="_blank">34818478</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Srinivasan.1">
<a name="Srinivasan.1"></a>Srinivasan R, Donskov F, Iliopoulos O, et al. Phase 2 study of belzutifan (MK-6482), an oral hypoxia-inducible factor 2α (HIF-2α) inhibitor, for Von Hippel-Lindau (VHL) disease-associated clear cell renal cell carcinoma (ccRCC). <i>J Clin Oncol</i>. 2021;39(suppl 15; abstr 4555). doi:10.1200/JCO.2021.39.15_suppl.4555</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-HHS.1">
<a name="HHS.1"></a>US Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. <a href="https://www.cdc.gov/niosh/docs/2016-161/default.html" target="_blank">https://www.cdc.gov/niosh/docs/2016-161/default.html</a>. Updated September 2016. Accessed August 16, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Welireg.1">
<a name="Welireg.1"></a>Welireg (belzutifan) [prescribing information]. Rahway, NJ: Merck Sharp &amp; Dohme LLC; December 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Welireg.1">
<a name="Welireg.1"></a>Welireg (belzutifan) [product monograph]. Kirkland, Quebec, Canada: Merck Canada Inc; July 2023.</div>
</li></ol></div><div id="topicVersionRevision">Topic 132401 Version 57.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
